ACADIA Pharmaceuticals Inc. (ACAD)
Company Info
| ISIN | US0042251084 |
|---|---|
| CUSIP | 004225108 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $2.52B |
|---|---|
| EPS (TTM) | $0.19 |
| PE Ratio | 79.84 |
| PEG Ratio | -0.42 |
| Total Revenue (TTM) | $678.84M |
| Gross Profit (TTM) | $619.76M |
| EBITDA (TTM) | $90.33M |
| Year Range | $14.31 - $32.59 |
| Target Price | $25.28 |
| Short % | 6.50% |
| Short Ratio | 5.86 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: ACAD vs. ABT, ACAD vs. TPR
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in ACADIA Pharmaceuticals Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
ACADIA Pharmaceuticals Inc. had a return of -51.13% year-to-date (YTD) and -33.28% in the last 12 months. Over the past 10 years, ACADIA Pharmaceuticals Inc. had an annualized return of -5.45%, while the S&P 500 had an annualized return of 11.71%, indicating that ACADIA Pharmaceuticals Inc. did not perform as well as the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -51.13% | 22.95% |
| 1 month | -6.31% | 4.39% |
| 6 months | -9.04% | 18.07% |
| 1 year | -33.28% | 37.09% |
| 5 years (annualized) | -17.49% | 14.48% |
| 10 years (annualized) | -5.45% | 11.71% |
Monthly Returns
The table below presents the monthly returns of ACAD, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -17.25% | -10.30% | -20.44% | -9.63% | -9.63% | 7.62% | 17.05% | -12.83% | -7.24% | -51.13% | |||
| 2023 | 19.54% | 8.72% | -9.04% | 13.34% | 10.17% | 1.91% | 22.09% | -7.59% | -22.87% | 8.30% | -1.28% | 40.53% | 96.67% |
| 2022 | -3.64% | 12.98% | -4.68% | -23.86% | -12.42% | -12.76% | 4.26% | 11.84% | -0.43% | -2.02% | -2.81% | 2.18% | -31.79% |
| 2021 | -10.12% | 1.91% | -47.31% | -20.31% | 8.66% | 9.18% | -11.32% | -19.05% | -5.14% | 8.07% | 6.96% | 21.56% | -56.34% |
| 2020 | -6.64% | 7.01% | -1.15% | 14.34% | 2.84% | -2.44% | -14.24% | -4.76% | 4.19% | 12.61% | 21.98% | -5.65% | 24.96% |
| 2019 | 40.88% | 16.33% | 1.32% | -10.43% | -0.25% | 11.42% | -8.04% | 12.53% | 30.12% | 17.84% | 6.79% | -5.54% | 164.56% |
| 2018 | -0.66% | -16.70% | -9.81% | -29.64% | 14.48% | -15.64% | -1.18% | -5.77% | 45.99% | -6.17% | -2.16% | -15.16% | -46.30% |
| 2017 | 19.94% | 10.18% | -9.79% | -0.15% | -25.11% | 8.48% | 6.74% | 19.62% | 5.78% | -7.54% | -13.15% | -0.46% | 4.40% |
| 2016 | -41.96% | -16.58% | 61.99% | 15.52% | 9.69% | -8.38% | 14.11% | -13.26% | -1.00% | -26.72% | 15.79% | 6.85% | -19.10% |
| 2015 | -4.16% | 24.78% | -14.17% | 4.85% | 20.57% | 1.65% | 16.55% | -24.95% | -9.72% | 5.29% | 8.99% | -6.06% | 12.28% |
| 2014 | -6.76% | 21.46% | -14.03% | -17.26% | 2.58% | 9.39% | -10.27% | 18.30% | 3.25% | 11.87% | 7.83% | 6.29% | 27.05% |
| 2013 | 29.68% | 0.66% | 30.81% | 62.34% | 9.15% | 29.00% | 8.54% | 1.32% | 37.63% | -17.27% | 2.49% | 7.30% | 437.42% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ACAD is 15, indicating that it is in the bottom 15% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the ACADIA Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ACADIA Pharmaceuticals Inc. was 96.29%, occurring on Nov 12, 2010. Recovery took 645 trading sessions.
The current ACADIA Pharmaceuticals Inc. drawdown is 73.16%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -96.29% | Mar 17, 2006 | 1175 | Nov 12, 2010 | 645 | Jun 10, 2013 | 1820 |
| -77.18% | Jul 8, 2020 | 493 | Jun 21, 2022 | — | — | — |
| -73.99% | Jul 20, 2015 | 777 | Aug 17, 2018 | 327 | Dec 5, 2019 | 1104 |
| -40.8% | Feb 28, 2014 | 32 | Apr 14, 2014 | 161 | Dec 2, 2014 | 193 |
| -38.42% | Dec 9, 2019 | 67 | Mar 16, 2020 | 29 | Apr 27, 2020 | 96 |
Volatility
Volatility Chart
The current ACADIA Pharmaceuticals Inc. volatility is 8.01%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of ACADIA Pharmaceuticals Inc. compared to its peers in the Biotechnology industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for ACAD in comparison to other companies of the Biotechnology industry. Currently, ACAD has a PE value of 79.8. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for ACAD in comparison to other companies of the Biotechnology industry. Currently, ACAD has a PEG value of -0.4. This PEG value is considered to be low compared to the rest of the industry.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for ACADIA Pharmaceuticals Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |